Usefulness of vena cava filters from clinicians view
Authors:
Otto Mayer; Zdenka Poklopová
Authors‘ workplace:
Oddělení klinické farmakologie FN Plzeň, prim. MUDr. David Suchý, Ph. D.
Published in:
Vnitř Lék 2015; 61(9): 799-804
Category:
Reviews
Overview
The indication for vena cava filters (VCF) in treatment of venous thromboembolism is still controversial. The presented overview should support the practical decisions. Beside of large volume of observational date there is only one study – PREPIC 1 – fulfilling requirements of prospective randomized design. During 8 years of follow up, pulmonary embolism (PE) was less frequent in the group with VCF than in the group without VCF, but at the cost of more frequent deep vein thrombosis (DVT). Other, but observational studies, showed similar results. Since last 10 years retrievable VCF are available. PREPIC 2 study was settled to prove, if use of retrievable VCF and their early removal will decrease the frequency of late complications observed in PREPIC 1. The results are available as conference abstract only, but it was presented that recurrence of DVT and PE was less frequent in group without IVC than with inserted VCF. Evaluation of impact of VCF insertion on mortality from RIETE registry showed only a trend which was in favour of VCF. On the other hand, a protective effect of VCF was demonstrated in hemodynamically unstable patients with PE (cardiogenic shock, massive embolism) with or without thrombolytic therapy evaluating cases from US NIS registry. Metaanalysis of studies in patients with polytrauma showed VCF protection mainly in patients where anticoagulation was contraindicated. Data gained from literature are discussed with existing guidelines. 2014 Recommendations of European Cardiologic Society is that VC filters may be used when there are absolute contraindications to anticoagulation and a high risk of VTE recurrence. The routine use of IVC filters in patients with PE is not recommended.
Key words:
deep vein thrombosis – pulmonary embolism – vena cava filters – venous thromboembolism
Sources
1. Widimský J. Diagnostika a léčba akutní plicní embolie v roce 2010. Vnitř Lék 2011; 57(1): 5–21.
2. Attia J, Rey JG,Deborah J et al.Deep Vein Thrombosis and Its Prevention in Critically Ill Adults. Arch Intern Med 2001; 161(10): 1268–1279.
3. Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism a clinical review. Blood Rev 2013; 27(5): 225–241.
4. Decousus H, Leizorovicz A, Parent F et al. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998; 338(7): 409–415.
5. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112(3): 416–422.
6. Hajduk B, Tomkowski WZ, Malek G et al.Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients, a prospective, observational cohort study. Chest 2010; 137(4): 877–882.
7. Imberti D, Ageno W, Dentali F et al. Retrievablevena cava filters: a clinical review. J Thromb Thrombolysis 2012; 33(3): 258–266.
8. Mismetti P, Ennezat PV, Quere I, et al. Prevention of pulmonary embolism recurrences by retrievable vena cava filter: results of the randomized multicenter trial PREPIC 2. XXIV. ISTH Congress 2013; Abstract AS 18.2.
9. 9.Stein PD, Matta F, Keyes DC et al. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med2012; 125(5): 478–484.
10. Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med 2014; 127(3): 222–225.
11. Muriel A, Jiménez D, Aujesky D et al. RIETE Investigators. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014; 63(16):1675–1683.
12. Kidane B, Madani AM, Vogt K et al. The use of prophylactic inferior vena cava filters in trauma patients: a systematic review. Injury 2012; 43(5): 542–547.
13. Haut ER, Garcia LJ, Shihab HMet al. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis JAMA Surg 2014; 149(2): 194–202.
14. Sarosiek S, Crowther M, Sloan JM Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med 2013; 173(7): 513–517.
15. Schunn C, Schunn GB, Hobbs G et al. Inferior vena cava filter placement in late-stage cancer. Vasc Endovascular Surg 2006; 40(4): 287–294.
16. Mansour A, Ismael Y, Abdel-Razeq HInferior vena cava filters in patients with advanced-stage cancer.Hematol Oncol Stem Cell Ther 2014; 7(4): 136–141.
17. Abtahian F, Hawkins BM, Ryan DP et al. Inferior vena cava filter usage, complications and retrieval rate in cancer patients. Am J Med 2014; 127(11): 1111–1117.
18. Sendon S,Dalmas AF, Lions F et al. Useof temporary inferior vena cava filter placement in pregnant women near term. Eur J Obstet Gynecol Reprod Biol 2008; 140(1): 143–144.
19. Bilger A, Pottecher J, Greget Met al. Extensive pulmonary embolism after severe postpartum haemorrhage: management with an inferior vena cava filter. Int J Obstet Anesth 2014; 23(4): 390–393.
20. Fox MA, Kahn SR. Postthrombotic syndrome in relation to vena cava filter placement: a systematic review. J Vasc Interv Radiol 2008; 19(7): 981–985.
21. Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004; 164(14): 1541–1545.
22. Harvey JJ, Hopkins J, McCafferty IJ et al. Inferior vena cava filters: what radiologists need to know. Clin Radiol 2013; 68(7): 721–732.
23. Segesser LK, Ferrari E, Tozzo P et al. Late removal of retrievable caval filtres. Swiss Med Wkly 2014; 144: w14022. Dostupné z DOI: <http://doi: 10.4414/smw.2014.14022. eCollection 2014>.
24. Tam MD, Spain J, Lieber M et al. Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications. J Vasc Interv Radiol 2012; 23(2): 199–205.
25. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal 2014; 35(43): 3033–3080.
26. Weinberger I, Kaufman J, Jaff MR. Inferior Vena Cava Filtres. JACC Cardiovasc Interv 2013; 6(6): 539–547.
27. Krajíček M, Peregrin J, Roček M et al. Chirurgická a intervenční léčba cévních onemocnění. Praha: Grada Publishing 2007. ISBN 978–80–247–06–07–8.
28. Reekers JA. Quality Improvement Guidelines for Percutaneous Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism. CIRSE European Standards. Dostupné z WWW: <http://www.cirse.org/?pid=755>.
29. Doporučení diagnostiky, léčby a prevence plicní embolie, verze 2007. Cor Vasa 2008; 50 (Suppl 1): 1S25–1S72.
30. Imberti D, Dentali F, Ageno W et al. Evidence and clinical judgment: vena cava filters. Thromb Haemost 2014; 111(4): 618–624.
31. Sader RB, Friedman A, Berkowitz E et al. Inferior vena cava filters and their varying compliance with the ACCP and the SIR guidelines. South Med J 2014; 107(9): 585–590.
32. Girard P, Meyer G, Parent F et al. Medical literature, vena cava filters and evidence of efficacy. A descriptive review. Thromb Haemost 2014; 111(4): 761–769.
33. Prasad V, Rho J, Cifu A. The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy? JAMA Intern Med 2013; 173(7): 493–495.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2015 Issue 9
Most read in this issue
- Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder
- Usefulness of vena cava filters from clinicians view
- Draft of the best medical treatment in patients with low-risk thyroid cancer
- Secondary humoral immunodeficiency in patiens with systemic lupus erythematosus